AC Immune (ACIU) Times Interest Earned (2015 - 2026)
AC Immune (ACIU) reported Times Interest Earned of $227.51 for Q1 2026, down 36.58% year-over-year from $358.7 in Q1 2025, and up 166.38% on a QoQ basis from -$342.71 in Q4 2025.
AC Immune (ACIU) has 12 years of Times Interest Earned data on file, last reported at $227.51 in Q1 2026.
- Quarterly Times Interest Earned fell 36.58% year-over-year to $227.51 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $542.76 (down 7.56% YoY) and the FY2025 annual result came in at -$366.76, up 8.27% from the prior year.
- Times Interest Earned rose to $227.51 in Q1 2026 per ACIU's latest filing, from -$342.71 in the prior quarter.
- Across five years, Times Interest Earned topped out at $631.33 in Q2 2023 and bottomed at -$564.18 in Q4 2024.
- The 5-year median for Times Interest Earned is $174.84 (2022), against an average of $162.17.
- The widest annual swing landed in 2023, when Times Interest Earned plunged 633.32%; it then jumped 407.73% in 2024.
- Tracing ACIU's Times Interest Earned over 5 years: stood at $26.56 in 2022, then tumbled by 633.32% to -$141.64 in 2023, then slumped by 298.32% to -$564.18 in 2024, then surged by 39.25% to -$342.71 in 2025, then surged by 166.38% to $227.51 in 2026.
- Per Business Quant, the three latest ACIU Times Interest Earned figures stand at $227.51 (Q1 2026), -$342.71 (Q4 2025), and $351.43 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -129.79 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3.58 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -258.33 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 11.50 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 49.84 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 3.88 |
| 10 | AC Immune | 325.88 Mn | 211.53 Mn | - | 227.51 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 227.51 |
| Dec 31, 2025 | -342.71 |
| Sep 30, 2025 | 351.43 |
| Jun 30, 2025 | 387.76 |
| Mar 31, 2025 | 358.70 |
| Dec 31, 2024 | -564.18 |
| Sep 30, 2024 | -220.27 |
| Jun 30, 2024 | 616.50 |
| Mar 31, 2024 | -573.37 |
| Dec 31, 2023 | 136.19 |
| Sep 30, 2023 | 594.85 |
| Jun 30, 2023 | 631.33 |
| Mar 31, 2023 | 181.14 |
| Dec 31, 2022 | -18,697.00 |
| Sep 30, 2022 | 174.84 |
| Jun 30, 2022 | 157.61 |
| Mar 31, 2022 | 122.27 |
| Dec 31, 2021 | 39.56 |
| Sep 30, 2021 | 112.06 |
| Jun 30, 2021 | 92.52 |
| Mar 31, 2021 | 8,625.50 |
| Dec 31, 2020 | 778.60 |
| Sep 30, 2020 | 408.80 |
| Jun 30, 2020 | 280.13 |
| Mar 31, 2020 | 1,825.50 |
| Dec 31, 2019 | 723.96 |
| Sep 30, 2019 | -209.03 |
| Jun 30, 2019 | 29.31 |
| Mar 31, 2019 | -20,052.00 |
| Dec 31, 2018 | 39.05 |
| Sep 30, 2018 | 392.61 |
| Jun 30, 2018 | 525.91 |
| Mar 31, 2018 | -870.92 |
| Dec 31, 2017 | 1.53 |
| Sep 30, 2017 | 2.10 |
| Jun 30, 2017 | -6.57 |
| Mar 31, 2017 | 4.79 |
| Dec 31, 2016 | -102.67 |
| Sep 30, 2016 | 7.61 |
| Mar 31, 2016 | 1,928.00 |
| Dec 31, 2015 | 233.56 |
| Sep 30, 2015 | -364.68 |